Lilly completes Phase 1 PK study of LY4268989 (MORF-057) in healthy volunteers
Registry record shows the trial's stated purpose was comparing two tablet formulations, though the design included a third.
- NCT07707375 is a completed Phase 1 trial of LY4268989, also known as MORF-057, sponsored by Eli Lilly and Company. The study's design, however, included three formulations labeled T1, T2 and T3, each tested under fed or fasted conditions across six treatment arms. Enrollment reached 50 participants.1 The study started on 2026-07-20 and reached primary completion on 2026-10-08, both actual dates.1 Primary outcomes measured were maximum concentration and area under the concentration curve for the drug.
Fact check notes
- Checker's noteThe phrase 'this week' in the summary is not supported by any date in the source; the only relevant dates are the completion date (2026-10-08) and last update posted (2026-11-16).
- Sentence removed
Eli Lilly closed out a single Phase 1 pharmacokinetics study this week.
unsupported: No source data indicates the closure happened 'this week'; only posting and completion dates are given. - Sentence removed
The purpose of the study is to identify if two different tablets of LY4268989 (MORF 057) work similarly in healthy participants given different meals.
copied source wording
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.